Market Spotlight: Neuroendocrine tumors (NET)
Market Spotlight: Neuroendocrine tumors (NET)
This Market Spotlight report covers the Neuroendocrine Tumors market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
This Market Spotlight report covers the Neuroendocrine Tumors market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- Datamonitor Healthcare estimates that in 2017, there were approximately 486,500 incident cases of neuroendocrine tumors (NETs) worldwide, and forecasts that number to increase to 586,100 incident cases by 2026.
- Worldwide, the majority of NETs in 2017 were malignant carcinoid tumors or neuroendocrine carcinomas. The approved drugs in the NETs space focus on targets such as norepinephrine (noradrenaline), radiopharmaceutical, mammalian target of rapamycin/mTORC, tyrosine hydroxylase, somatostatin receptors, FMS-like tyrosine kinase 3, KIT/c-KIT, platelet-derived growth factor receptor, VEGF receptor, ganglioside GD2, and tryptophan hydroxylase. These drugs are predominantly administered via the oral, intravenous, and subcutaneous routes, while one product is available in an intramuscular formulation.
- The majority of industry-sponsored drugs in active clinical development for NETs are in Phase II, with only one product in Phase III.
- Therapies in the pipeline for NETs focus on a wide variety of targets. The largest proportion of these therapies are being administered intravenously, with the remainder being oral, subcutaneous, intranasal, intramuscular, and intratumoral formulations.
- The only high-impact upcoming events for drugs in the NETs space are topline Phase III results from two trials of sulfatinib. The overall likelihood of approval of a Phase I solid tumors asset is 5.8%, and the average probability a drug advances from Phase III is 40.3%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space. • There have been only six licensing and asset acquisition deals involving NETs drugs during 2014–19. The $115m exclusive licensing agreement signed in November 2017 between NanoCarrier and VBL Therapeutics for the development, commercialization, and supply of VB-111 (ofranergene obadenovec) in Japan was the only deal with a disclosed value.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for NETs have been in the early and midphases of development, with 78% of trials in Phase I–II, and only 22% in Phase III–IV.
- The US has a substantial lead in the number of NETs clinical trials globally. The UK leads the major EU markets, while China has the top spot in Asia.
- Novartis has the highest number of completed clinical trials for NETs, with 16 trials. Novartis also leads industry sponsors with the highest overall number of clinical trials for NETs, followed by Ipsen and Pfizer.
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 Hepatic artery embolization
9 Somatostatin analogs
9 Interferon-alpha (IFN-alpha)
10 Radiation therapy
10 Targeted therapy
10 Palliative care
11 Incidence methodology
11 Disease definition
15 Prevalence methodology
17 MARKETED DRUGS
20 PIPELINE DRUGS
28 RECENT EVENTS AND ANALYST OPINION
28 TBR-760 for NETs (January 3, 2019)
29 Qarziba for NETs (June 2, 2018)
31 KEY UPCOMING EVENTS
32 KEY REGULATORY EVENTS
32 Radiopharmaceutical Azedra Approved To Treat Rare NETs
33 PROBABILITY OF SUCCESS
34 LICENSING AND ASSET ACQUISITION DEALS
35 PARENT PATENTS
36 REVENUE OPPORTUNITY
37 CLINICAL TRIAL LANDSCAPE
38 Sponsors by status
39 Sponsors by phase
41 Prescription information
LIST OF FIGURES
14 Figure 1: Trends in incident cases of NETs, 2017–26
15 Figure 2: Incident cases of NETs, by tumor type, 2017
20 Figure 3: Overview of pipeline drugs for NETs in the US
20 Figure 4: Pipeline drugs for NETs, by company
21 Figure 5: Pipeline drugs for NETs, by drug type
21 Figure 6: Pipeline drugs for NETs, by classification
30 Figure 7: Qarziba for NETs (June 2, 2018): Phase III – HR-NBL-1 (1.5) (EU)
31 Figure 8: Key upcoming events in NETs
33 Figure 9: Probability of success in the NETs pipeline
34 Figure 10: Licensing and asset acquisition deals in NETs, 2014–19
35 Figure 11: Parent patents in NETs
37 Figure 12: Clinical trials in NETs
37 Figure 13: Top 10 drugs for clinical trials in NETs
38 Figure 14: Top 10 companies for clinical trials in NETs
38 Figure 15: Trial locations in NETs
39 Figure 16: NETs trials status
40 Figure 17: NETs trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of NETs, 2017–26
16 Table 2: Five-year prevalent cases of NETs, 2017–26
18 Table 3: Marketed drugs for NETs
22 Table 4: Pipeline drugs for NETs in the US
28 Table 5: TBR-760 for NETs (January 3, 2019)
29 Table 6: Qarziba for NETs (June 2, 2018)
36 Table 7: Historical global sales, by drug ($m), 2014–18
36 Table 8: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email email@example.com for further help or assistance.